Trimodality PET/CT/MRI and Radiotherapy: A Mini-Review

Overview

Journal Front Oncol

Specialty Oncology

Date 2021 Feb 22

PMID 33614497

Citations 14

Authors

Pierre Decazes

Pauline Hinault

Ovidiu Veresezan

Sebastien Thureau

Pierrick Gouel

Pierre Vera

Affiliations

Soon will be listed here.

Abstract

Computed tomography (CT) has revolutionized external radiotherapy by making it possible to visualize and segment the tumors and the organs at risk in a three-dimensional way. However, if CT is a now a standard, it presents some limitations, notably concerning tumor characterization and delineation. Its association with functional and anatomical images, that are positron emission tomography (PET) and magnetic resonance imaging (MRI), surpasses its limits. This association can be in the form of a trimodality PET/CT/MRI. The objective of this mini-review is to describe the process of performing this PET/CT/MRI trimodality for radiotherapy and its potential clinical applications. Trimodality can be performed in two ways, either a PET/MRI fused to a planning CT (possibly with a pseudo-CT generated from the MRI for the planning), or a PET/CT fused to an MRI and then registered to a planning CT (possibly the CT of PET/CT if calibrated for radiotherapy). These examinations should be performed in the treatment position, and in the second case, a patient transfer system can be used between the PET/CT and MRI to limit movement. If trimodality requires adapted equipment, notably compatible MRI equipment with high-performance dedicated coils, it allows the advantages of the three techniques to be combined with a synergistic effect while limiting their disadvantages when carried out separately. Trimodality is already possible in clinical routine and can have a high clinical impact and good inter-observer agreement, notably for head and neck cancers, brain tumor, prostate cancer, cervical cancer.

Citing Articles

Exploring and Anticipating the Applications of Organic Room-Temperature Phosphorescent Materials in Biomedicine and Dentistry.

Zhang Y, Zhu Y, Deng T, Du Y Int J Nanomedicine. 2024; 19():13201-13216.

PMID: 39670197 PMC: 11636246. DOI: 10.2147/IJN.S492759.

Cardiac substructure delineation in radiation therapy - A state-of-the-art review.

Finnegan R, Quinn A, Booth J, Belous G, Hardcastle N, Stewart M J Med Imaging Radiat Oncol. 2024; 68(8):914-949.

PMID: 38757728 PMC: 11686467. DOI: 10.1111/1754-9485.13668.

Synthetic CT generation from MRI using 3D transformer-based denoising diffusion model.

Pan S, Abouei E, Wynne J, Chang C, Wang T, Qiu R Med Phys. 2023; 51(4):2538-2548.

PMID: 38011588 PMC: 10994752. DOI: 10.1002/mp.16847.

The Role of MRI and PET/CT in Radiotherapy Target Volume Determination in Gastrointestinal Cancers-Review of the Literature.

Secerov Ermenc A, Segedin B Cancers (Basel). 2023; 15(11).

PMID: 37296929 PMC: 10252061. DOI: 10.3390/cancers15112967.

Exosomes and ultrasound: The future of theranostic applications.

Sridharan B, Lim H Mater Today Bio. 2023; 19:100556.

PMID: 36756211 PMC: 9900624. DOI: 10.1016/j.mtbio.2023.100556.

References

Zamboglou C, Thomann B, Koubar K, Bronsert P, Krauss T, Rischke H . Focal dose escalation for prostate cancer using Ga-HBED-CC PSMA PET/CT and MRI: a planning study based on histology reference. Radiat Oncol. 2018; 13(1):81. PMC: 5930745. DOI: 10.1186/s13014-018-1036-8. View

Nishioka T, Shiga T, Shirato H, Tsukamoto E, Tsuchiya K, Kato T . Image fusion between 18FDG-PET and MRI/CT for radiotherapy planning of oropharyngeal and nasopharyngeal carcinomas. Int J Radiat Oncol Biol Phys. 2002; 53(4):1051-7. DOI: 10.1016/s0360-3016(02)02854-7. View

Peng Y, Chen S, Qin A, Chen M, Gao X, Liu Y . Magnetic resonance-based synthetic computed tomography images generated using generative adversarial networks for nasopharyngeal carcinoma radiotherapy treatment planning. Radiother Oncol. 2020; 150:217-224. DOI: 10.1016/j.radonc.2020.06.049. View

Maspero M, Savenije M, Dinkla A, Seevinck P, Intven M, Jurgenliemk-Schulz I . Dose evaluation of fast synthetic-CT generation using a generative adversarial network for general pelvis MR-only radiotherapy. Phys Med Biol. 2018; 63(18):185001. DOI: 10.1088/1361-6560/aada6d. View

Grubmuller B, Baltzer P, Hartenbach S, DAndrea D, Helbich T, Haug A . PSMA Ligand PET/MRI for Primary Prostate Cancer: Staging Performance and Clinical Impact. Clin Cancer Res. 2018; 24(24):6300-6307. DOI: 10.1158/1078-0432.CCR-18-0768. View

Lai A, Perucho J, Xu X, Hui E, Lee E . Concordance of FDG PET/CT metabolic tumour volume versus DW-MRI functional tumour volume with T2-weighted anatomical tumour volume in cervical cancer. BMC Cancer. 2017; 17(1):825. PMC: 5718076. DOI: 10.1186/s12885-017-3800-9. View

Hayes A, Jayamanne D, Hsiao E, Schembri G, Bailey D, Roach P . Utilizing 18F-fluoroethyltyrosine (FET) positron emission tomography (PET) to define suspected nonenhancing tumor for radiation therapy planning of glioblastoma. Pract Radiat Oncol. 2018; 8(4):230-238. DOI: 10.1016/j.prro.2018.01.006. View

Paulus D, Oehmigen M, Gruneisen J, Umutlu L, Quick H . Whole-body hybrid imaging concept for the integration of PET/MR into radiation therapy treatment planning. Phys Med Biol. 2016; 61(9):3504-20. DOI: 10.1088/0031-9155/61/9/3504. View

Pathmanathan A, Alexander E, Huddart R, Tree A . The delineation of intraprostatic boost regions for radiotherapy using multimodality imaging. Future Oncol. 2016; 12(21):2495-2511. DOI: 10.2217/fon-2016-0129. View

10.

Guo L, Shen S, Harris E, Wang Z, Jiang W, Guo Y . A tri-modality image fusion method for target delineation of brain tumors in radiotherapy. PLoS One. 2014; 9(11):e112187. PMC: 4223022. DOI: 10.1371/journal.pone.0112187. View

11.

Huang Y, Chen J, Chen J, Lee Y, Huang J, Kuo S . Predicting tumor responses and patient survival in chemoradiotherapy-treated patients with non-small-cell lung cancer using dynamic contrast-enhanced integrated magnetic resonance-positron-emission tomography. Strahlenther Onkol. 2019; 195(8):707-718. DOI: 10.1007/s00066-018-1418-8. View

12.

Prestwich R, Sykes J, Carey B, Sen M, Dyker K, Scarsbrook A . Improving target definition for head and neck radiotherapy: a place for magnetic resonance imaging and 18-fluoride fluorodeoxyglucose positron emission tomography?. Clin Oncol (R Coll Radiol). 2012; 24(8):577-89. DOI: 10.1016/j.clon.2012.04.002. View

13.

Hirata T, Kinoshita M, Tamari K, Seo Y, Suzuki O, Wakai N . 11C-methionine-18F-FDG dual-PET-tracer-based target delineation of malignant glioma: evaluation of its geometrical and clinical features for planning radiation therapy. J Neurosurg. 2018; 131(3):676-686. DOI: 10.3171/2018.4.JNS1859. View

14.

Braendengen M, Hansson K, Radu C, Siegbahn A, Jacobsson H, Glimelius B . Delineation of gross tumor volume (GTV) for radiation treatment planning of locally advanced rectal cancer using information from MRI or FDG-PET/CT: a prospective study. Int J Radiat Oncol Biol Phys. 2011; 81(4):e439-45. DOI: 10.1016/j.ijrobp.2011.03.031. View

15.

Graf R, Plotkin M, Steffen I, Wurm R, Wust P, Brenner W . Magnetic resonance imaging, computed tomography, and 68Ga-DOTATOC positron emission tomography for imaging skull base meningiomas with infracranial extension treated with stereotactic radiotherapy--a case series. Head Face Med. 2012; 8:1. PMC: 3274469. DOI: 10.1186/1746-160X-8-1. View

16.

Decazes P, Thureau S, DuBray B, Vera P . How to use PET/CT in the evaluation of response to radiotherapy. Q J Nucl Med Mol Imaging. 2017; 62(2):152-164. DOI: 10.23736/S1824-4785.17.03033-3. View

17.

Daisne J, Sibomana M, Bol A, Cosnard G, Lonneux M, Gregoire V . Evaluation of a multimodality image (CT, MRI and PET) coregistration procedure on phantom and head and neck cancer patients: accuracy, reproducibility and consistency. Radiother Oncol. 2003; 69(3):237-45. DOI: 10.1016/j.radonc.2003.10.009. View

18.

Walacides D, Meier A, Knochelmann A, Meinecke D, Derlin T, Bengel F . Comparison of  Ga-PSMA ligand PET/CT versus conventional cross-sectional imaging for target volume delineation for metastasis-directed radiotherapy for metachronous lymph node metastases from prostate cancer. Strahlenther Onkol. 2019; 195(5):420-429. DOI: 10.1007/s00066-018-1417-9. View

19.

Gwynne S, Mukherjee S, Webster R, Spezi E, Staffurth J, Coles B . Imaging for target volume delineation in rectal cancer radiotherapy--a systematic review. Clin Oncol (R Coll Radiol). 2011; 24(1):52-63. DOI: 10.1016/j.clon.2011.10.001. View

20.

Gardner M, Halimi P, Valinta D, Plantet M, Alberini J, Wartski M . Use of single MRI and 18F-FDG PET-CT scans in both diagnosis and radiotherapy treatment planning in patients with head and neck cancer: advantage on target volume and critical organ delineation. Head Neck. 2008; 31(4):461-7. DOI: 10.1002/hed.21005. View